SRI 31215 TFA |
| Catalog No.GC34811 |
SRI 31215(TFA)는 매트립타제/헵신/간세포 성장 인자 활성화제(HGFA) 삼중 억제제이며 HAI-1/2(HGF 활성화의 내인성 억제제)의 활성을 모방합니다. SRI 31215는 IC50 값이 각각 0.69μM, 0.65μM 및 0.30μM인 matriptase, hepsin 및 HGFA에 대한 강력한 억제 활성을 가지고 있습니다. SRI 31215는 암 연구에 사용할 수 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1832686-44-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SRI 31215 (TFA), a triplex inhibitor of matriptase, hepsin and hepatocyte growth factor activator (HGFA) with IC50s of 0.69 μM, 0.65 μM, 0.3 μM, blocks pro-HGF activation and thus mimics the activity of HAI-1/2[1]. IC50: 0.69 μM (matriptase), 0.65 μM (hepsin), 0.3 μM (HGFA)[1]
[1]. Owusu BY, et al. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget. 2016 May 17;7(20):29492-506.
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *